organization · Reporting owner

BB BIOTECH AG

Disclosed activity across 7 companies

Tapewire entity: 81733
SEC CIK: 0000924223

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cidara Therapeutics, Inc.CDTX · Entity 69639	10% owner	November 15, 2017	November 16, 2017
Esperion Therapeutics, Inc.ESPR · Entity 30796	10% owner	May 24, 2021	May 26, 2021
MACROGENICS INCMGNX · Entity 6104	10% owner	October 02, 2023	October 04, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cidara Therapeutics, Inc.

Report date November 15, 2017 · Filed November 16, 2017

Jointly reported with BIOTECH TARGET N V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,295,272	Reported balance After 2017-11-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-11-15 · Purchase · Acquired 60,000 · Balance 2,295,272

Esperion Therapeutics, Inc.

Report date May 24, 2021 · Filed May 26, 2021

Jointly reported with BIOTECH TARGET N V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,477,964	Reported balance After 2021-05-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-24 · Purchase · Acquired 100,000 · Balance 4,477,964

MACROGENICS INC

Report date October 02, 2023 · Filed October 04, 2023

Jointly reported with BIOTECH TARGET N V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,929,963	Reported balance After 2023-10-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-10-02 · Purchase · Acquired 150,000 · Balance 9,929,963

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Black Diamond Therapeutics, Inc.

Report date March 19, 2025 · Filed March 21, 2025

Jointly reported with BIOTECH GROWTH N V

Section 16 reporting ended · disclosed 2025-03-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,517,839	Reported balance After 2025-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-03-19 · Sale · Disposed 1,000,000 · Balance 7,517,839
Common StockSEC Table I · non-derivative	Direct	7,217,839	Reported balance After 2025-03-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-03-19 · Sale · Disposed 300,000 · Balance 7,217,839
Common StockSEC Table I · non-derivative	Direct	6,217,839	Reported balance After 2025-03-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-03-19 · Sale · Disposed 1,000,000 · Balance 6,217,839
Common StockSEC Table I · non-derivative	Direct	4,217,839	Reported balance After 2025-03-19 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2025-03-19 · Sale · Disposed 2,000,000 · Balance 4,217,839
Common StockSEC Table I · non-derivative	Direct	3,817,839	Reported balance After 2025-03-19 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2025-03-19 · Sale · Disposed 400,000 · Balance 3,817,839
Common StockSEC Table I · non-derivative	Direct	3,233,547	Reported balance After 2025-03-19 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2025-03-19 · Sale · Disposed 584,292 · Balance 3,233,547
Common StockSEC Table I · non-derivative	Direct	2,733,547	Reported balance After 2025-03-19 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2025-03-19 · Sale · Disposed 500,000 · Balance 2,733,547

ESSA Pharma Inc.

Report date November 01, 2024 · Filed November 05, 2024

Jointly reported with BIOTECH GROWTH N V

Section 16 reporting ended · disclosed 2024-11-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	5,879,583	Reported balance After 2024-11-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 5,879,583
Common SharesSEC Table I · non-derivative	Direct	3,879,583	Reported balance After 2024-11-01 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 3,879,583
Common SharesSEC Table I · non-derivative	Direct	1,879,583	Reported balance After 2024-11-01 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 1,879,583
Common SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2024-11-01 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-11-01 · Sale · Disposed 1,879,583 · Balance 0

Molecular Templates, Inc.

Report date November 14, 2024 · Filed November 19, 2024

Jointly reported with BIOTECH TARGET N V

Section 16 reporting ended · disclosed 2024-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-11-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-11-14 · Sale · Disposed 1,279,820 · Balance 0
Prefunded Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	134,667	Reported balance After 2024-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-04-02 · Purchase · Acquired 134,667 · Balance 134,667 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.
Common Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2029-04-02	Direct	769,334	Reported balance After 2024-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-04-02 · Purchase · Acquired 769,334 · Balance 769,334 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

Filing footnotes · ownership attribution and instrument terms

F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

Radius Health, Inc.

Report date August 15, 2022 · Filed August 30, 2022

Jointly reported with BIOTECH TARGET N V

Section 16 reporting ended · disclosed 2022-08-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-08-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-08-11 · Other · Disposed 8,733,538 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 03, 2020 Filed Nov 4, 2020 21:37 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	200,000	$25.31	$5,062,120.00	Disclosure SEC source: 0000899243-20-030389 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,947,964 Read SEC document
October 30, 2020 Filed Nov 4, 2020 20:05 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$8.83	$706,312.00	Disclosure SEC source: 0000899243-20-030364 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,229,996 Read SEC document
October 28, 2020 Filed Nov 4, 2020 20:05 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$9.40	$751,688.00	Disclosure SEC source: 0000899243-20-030364 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,149,996 Read SEC document
September 14, 2020 Filed Sep 16, 2020 16:01 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	200,000	$11.69	$2,338,680.00	Disclosure SEC source: 0000899243-20-025283 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,355,714 Read SEC document
September 11, 2020 Filed Sep 14, 2020 20:03 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	199,029	$11.33	$2,255,117.99	Disclosure SEC source: 0000899243-20-024980 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,155,714 Read SEC document
July 08, 2020 Filed Jul 9, 2020 18:40 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	25,000	$13.21	$330,177.50	Disclosure SEC source: 0000899243-20-018807 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,956,685 Read SEC document
April 30, 2020 Filed May 4, 2020 21:32 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$15.75	$787,555.00	Disclosure SEC source: 0000899243-20-011906 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,931,685 F1 · balance_after: Includes 6,881,685 shares of common stock previously held by Biotech Growth N.V. Biotech Growth N.V. and Biotech Target N.V. are both wholly-owned subsidiaries of BB Biotech AG. Read SEC document
January 23, 2020 Filed Jan 27, 2020 17:51 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	20,000	$52.12	$1,042,398.00	Disclosure SEC source: 0000899243-20-002016 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,747,964 Read SEC document
November 06, 2019 Filed Nov 8, 2019 19:54 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	75,000	$37.30	$2,797,560.00	Disclosure SEC source: 0000899243-19-026965 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,727,964 Read SEC document
November 06, 2019 Filed Nov 8, 2019 19:52 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	100,000	$23.00	$2,300,300.00	Disclosure SEC source: 0000899243-19-026963 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,881,685 Read SEC document
September 04, 2019 Filed Sep 6, 2019 20:09 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	80,000	$33.78	$2,702,208.00	Disclosure SEC source: 0000899243-19-022997 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,652,964 Read SEC document
July 23, 2019 Filed Jul 25, 2019 16:42 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	50,000	$42.65	$2,132,565.00	Disclosure SEC source: 0000899243-19-020344 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,572,964 Read SEC document
March 14, 2019 Filed Mar 15, 2019 23:50 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	50,000	$49.89	$2,494,355.00	Disclosure SEC source: 0000899243-19-008014 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,522,964 Read SEC document
February 14, 2019 Filed Feb 19, 2019 16:04 UTC	Radius Health, Inc. RDUS · Entity 124173	OtherCommon Stock Warrant (right to buy) · Derivative	71,409	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0000899243-19-003965 · doc4.xml · derivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,409 shares Expires 2014-02-19 Read SEC document
February 14, 2019 Filed Feb 19, 2019 16:04 UTC	Radius Health, Inc. RDUS · Entity 124173	OtherCommon Stock	71,409	$14.00	$1,000,011.64	Disclosure SEC source: 0000899243-19-003965 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,781,685 Read SEC document
January 04, 2019 Filed Jan 7, 2019 22:10 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	80,000	$41.29	$3,303,256.00	Disclosure SEC source: 0000899243-19-000685 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,472,964 Read SEC document
December 24, 2018 Filed Dec 26, 2018 16:44 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	50,000	$39.91	$1,995,725.00	Disclosure SEC source: 0000899243-18-031655 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,392,964 Read SEC document
December 20, 2018 Filed Dec 21, 2018 17:00 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	60,000	$14.48	$868,782.00	Disclosure SEC source: 0000899243-18-031549 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,710,276 Read SEC document
December 17, 2018 Filed Dec 19, 2018 18:14 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	60,000	$47.73	$2,864,070.00	Disclosure SEC source: 0000899243-18-031388 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,342,964 Read SEC document
December 14, 2018 Filed Dec 17, 2018 20:35 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	60,000	$15.64	$938,256.00	Disclosure SEC source: 0000899243-18-031191 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,650,276 Read SEC document
August 20, 2018 Filed Aug 22, 2018 15:08 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	60,000	$19.65	$1,178,808.00	Disclosure SEC source: 0000899243-18-022966 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,590,276 Read SEC document
August 15, 2018 Filed Aug 16, 2018 19:18 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	69,363	$20.78	$1,441,529.61	Disclosure SEC source: 0000899243-18-022543 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,530,276 Read SEC document
August 14, 2018 Filed Aug 16, 2018 19:18 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	100,000	$20.87	$2,086,880.00	Disclosure SEC source: 0000899243-18-022543 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,460,913 Read SEC document
August 08, 2018 Filed Aug 10, 2018 19:04 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	60,000	$22.73	$1,363,884.00	Disclosure SEC source: 0000899243-18-022027 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,360,913 Read SEC document
August 03, 2018 Filed Aug 6, 2018 19:23 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	50,000	$46.14	$2,306,970.00	Disclosure SEC source: 0000899243-18-021471 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,282,964 Read SEC document
July 27, 2018 Filed Jul 30, 2018 21:23 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$24.81	$1,240,605.00	Disclosure SEC source: 0000899243-18-020772 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300,913 Read SEC document
July 25, 2018 Filed Jul 26, 2018 18:56 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$27.28	$1,363,805.00	Disclosure SEC source: 0000899243-18-020649 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250,913 Read SEC document
July 12, 2018 Filed Jul 13, 2018 15:45 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	50,000	$41.77	$2,088,300.00	Disclosure SEC source: 0000899243-18-019836 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,232,964 Read SEC document
June 29, 2018 Filed Jul 3, 2018 15:55 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	50,000	$39.48	$1,973,805.00	Disclosure SEC source: 0000899243-18-019108 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,182,964 Read SEC document
June 21, 2018 Filed Jun 25, 2018 16:43 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	60,000	$38.57	$2,314,224.00	Disclosure SEC source: 0000899243-18-017843 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,132,964 Read SEC document
June 11, 2018 Filed Jun 13, 2018 19:29 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$27.36	$1,367,835.00	Disclosure SEC source: 0000899243-18-016344 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200,913 Read SEC document
June 07, 2018 Filed Jun 11, 2018 18:59 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	60,000	$37.79	$2,267,292.00	Disclosure SEC source: 0000899243-18-015926 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,072,964 Read SEC document
June 05, 2018 Filed Jun 7, 2018 18:34 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	60,000	$38.47	$2,308,440.00	Disclosure SEC source: 0000899243-18-015413 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012,964 Read SEC document
May 23, 2018 Filed May 24, 2018 18:29 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	40,000	$28.91	$1,156,320.00	Disclosure SEC source: 0000899243-18-013884 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,150,913 Read SEC document
May 21, 2018 Filed May 22, 2018 19:49 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	80,000	$38.77	$3,101,760.00	Disclosure SEC source: 0000899243-18-013665 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,952,964 Read SEC document
May 21, 2018 Filed May 23, 2018 18:42 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	60,000	$29.27	$1,756,380.00	Disclosure SEC source: 0000899243-18-013810 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,110,913 Read SEC document
May 18, 2018 Filed May 22, 2018 19:49 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	50,000	$42.24	$2,112,010.00	Disclosure SEC source: 0000899243-18-013665 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,872,964 Read SEC document
April 19, 2018 Filed Apr 23, 2018 17:28 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	40,000	$33.80	$1,351,936.00	Disclosure SEC source: 0000899243-18-010551 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,050,913 Read SEC document
April 12, 2018 Filed Apr 16, 2018 18:07 UTC	Radius Health, Inc. RDUS · Entity 124173	OtherCommon Stock Warrant (right to buy) · Derivative	107,114	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0000899243-18-010183 · doc4.xml · derivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,409 Underlying: Common Stock · 107,114 shares Expires 2018-04-23 Read SEC document
April 12, 2018 Filed Apr 16, 2018 18:07 UTC	Radius Health, Inc. RDUS · Entity 124173	OtherCommon Stock	107,114	$14.00	$1,500,024.46	Disclosure SEC source: 0000899243-18-010183 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,010,913 Read SEC document
April 05, 2018 Filed Apr 9, 2018 17:19 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$36.58	$1,828,845.00	Disclosure SEC source: 0000899243-18-009722 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,903,799 Read SEC document
March 02, 2018 Filed Mar 6, 2018 21:23 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	80,000	$32.52	$2,601,448.00	Disclosure SEC source: 0000899243-18-006482 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,853,799 Read SEC document
February 09, 2018 Filed Feb 12, 2018 21:54 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	75,000	$34.38	$2,578,762.50	Disclosure SEC source: 0000899243-18-003551 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,773,799 Read SEC document
November 15, 2017 Filed Nov 16, 2017 17:19 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	60,000	$7.57	$453,966.00	Disclosure SEC source: 0000899243-17-026540 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,295,272 Read SEC document
November 14, 2017 Filed Nov 16, 2017 17:16 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$26.25	$1,312,390.00	Disclosure SEC source: 0000899243-17-026538 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,698,799 Read SEC document
November 03, 2017 Filed Nov 7, 2017 17:44 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$29.15	$1,457,575.00	Disclosure SEC source: 0000899243-17-025497 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,648,799 Read SEC document
October 26, 2017 Filed Oct 27, 2017 19:39 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$30.95	$1,547,550.00	Disclosure SEC source: 0000899243-17-024807 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,598,799 Read SEC document
October 25, 2017 Filed Oct 26, 2017 22:30 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$32.85	$1,642,415.00	Disclosure SEC source: 0000899243-17-024774 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,548,799 Read SEC document
September 14, 2017 Filed Sep 15, 2017 18:05 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	50,000	$32.94	$1,647,225.00	Disclosure SEC source: 0000899243-17-022128 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,498,799 Read SEC document
September 13, 2017 Filed Sep 15, 2017 18:05 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	100,000	$33.71	$3,370,750.00	Disclosure SEC source: 0000899243-17-022128 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,448,799 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.